Loading
Overweight , Obesity / MWN105 3 / MWN105 1 · Phase 2 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 clinical trial registration for MWN105 Injection, a subcutaneous drug candidate for overweight or obesity in non-diabetic adults. The trial has completed recruitment of 120 participants randomized to three dose levels or placebo, with body weight change at 24 weeks as the primary endpoint. No outcome results are posted in this registry record.
Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Overweight , Obesity; age from 18 Years; to 65 Years. Intervention: MWN105 Cohort 1; MWN105 Cohort 2; MWN105 Cohort 3. Compared with: Placebo — Placebo Comparator. n = 120. 1 site: China.
This is a Phase 2 clinical trial registration for MWN105 Injection, a subcutaneous drug candidate for overweight or obesity in non-diabetic adults. The trial has completed recruitment of 120 participants randomized to three dose levels or placebo, with body weight change at 24 weeks as the primary endpoint. No outcome results are posted in this registry record.
Secondary endpoints include metabolic parameters and bone mineral density, but efficacy and safety data are not available in this record.
The source did not state who this applies to in practice.
Phase 2 trial with planned enrollment of 120 participants and surrogate endpoint (percent change in body weight); results are not yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07804810). This is a study registration, not published results. Lead sponsor: Shanghai Minwei Biotechnology Co., Ltd. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 120 participants (ACTUAL). Conditions: Overweight , Obesity. Interventions: DRUG: MWN105 1; DRUG: MWN105 2; DRUG: MWN105 3; DRUG: Placebo. Primary outcome measures: Percentage Change from Baseline in Body Weight at Week 24. , Baseline, Week 24. Brief summary: This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 Injection in non-diabetic participants with overweight or obesity. Approximately 120 participants will be randomized to receive different dose levels of MWN105 Injection or matching placebo, administered subcutaneously once weekly for a total treatment duration of 24 weeks, with dose titration from 15 mg to the target dose. The primary endpoint is the percent change from baseline in body weight at Week 24. Secondary endpoints include changes in body weight and metabolic parameters, bone mineral density, pharmacokinetic parameters, immunogenicity, and safety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.